T-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients
Lophius Biosciences GmbH today announced the publication of a peer-reviewed scientific paper covering the company's CE-marked in vitro diagnostic test T-Track® CMV in a clinical study with kidney transplant patients
(PresseBox) - Lophius Biosciences GmbH today announced the publication of a peer-reviewed scientific paper covering the company?s CE-marked in vitro diagnostic test T-Trackinical complications. The paper was published in Transplant International1).
In this prospective longitudinal multicenter study, 86 kidney transplant recipients were followed over 6 months post-transplantation. CMV-specific cell-mediated immunity was monitored using T-Tracke significantly higher in patients with a protective immunity, compared to patients requiring antiviral treatment, highlighting the potential predictive value of the assay.
?The recent publication nicely shows that T-Trackforward to broaden the routine use of our test and making the clinical advantages available to a large number of transplant patients?, said Bernd Merkl, CEO & Managing Director of Lophius Biosciences GmbH.
1)Banas et al. (2017). Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-speci?c cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. doi: 10.1111/tri.13110.
Background CMV, CMV-specific cell-mediated immunity & T-Track
The replication of CMV, with a high seroprevalence in the human population of 30-90%, is efficiently controlled in healthy individuals by the immune system primarily via cell-mediated immunity. To avoid uncontrolled CMV replication, immunosuppressed patients like transplant recipients are treated with antiviral medication either prophylactically in the first months after transplantation or preemptively based on CMV viral load measurement. However, optimal duration of either prophylaxis or of virological monitoring is not well defined. In the current setting, assessment of CMV-specific immunity and the ability of immunosuppressed patients to control virus replication via their immune system are not taken into consideration. On the one hand this may result in overtreatment of patients with reconstituted and protective CMV immunity. Avoiding unnecessary antiviral treatment would prevent unwanted side effects for the patients and increased costs for the healthcare system. On the other hand it may expose patients with delayed immune reconstitution to higher risk for CMV disease. Therefore, it is equally important to identify these patients with CMV-specific immunity monitoring.
By measuring CMV-specific cell-mediated immunity, T-Track help clinicians in their decision to start, discontinue or adjust antiviral treatment.
Lophius Biosciences is a privately held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company?s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.
With its T-Trackoward an improved and individualized patient management.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Lophius Biosciences is a privately held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company?s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells toaccurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.With its T-Track® CMV leading product, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.
Datum: 08.02.2018 - 11:27 Uhr
Sprache: Deutsch
News-ID 1532405
Anzahl Zeichen: 4195
contact information:
Contact person:
Town:
Regensburg
Phone:
Kategorie:
Handcrafts
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 1101 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"T-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients
"
steht unter der journalistisch-redaktionellen Verantwortung von
Lophius Biosciences GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
